Ziemer Announces GALILEI ColorZ With ZEISS VERACITY Surgical Compatibility

Ziemer Announces GALILEI ColorZ With ZEISS VERACITY Surgical Compatibility

ALTON, Ill. - September 29, 2022 - (Newswire.com)

Ziemer USA, Inc., a wholly owned subsidiary of Ziemer Group AG (Port, Switzerland), a developer and manufacturer of the Femtosecond Laser Technology (FEMTO LDV Z8) and Corneal Diagnostic equipment (GALILEI ColorZ), announces the introduction of GALILEI ColorZ with ZEISS VERACITY Surgical compatibility.

"We continue to invest in new technologies making it easier for our customers and surgeons to deliver great patient outcomes every day. We are excited about the upgrades we have made with the GALILEI ColorZ and the connectivity offered with ZEISS VERACITY Surgical", says David Bragg, President of Ziemer USA & Canada.

The GALILEI ColorZ G4 and G6 represent the new generation of the renowned diagnostic platform, offering multilayer TopView images in vibrant colors and high contrast to provide enhanced visualization of numerous details including blood vessels, iris patterns and the pupil. Now, with access to ZEISS VERACITY Surgical, the GALILEI ColorZ G6 is the all-in-one device that takes refractive cataract surgery planning to the next level.

ABOUT ZIEMER USA, INC.

Ziemer believes in constantly innovating and improving technology to better serve our doctors. Our Swiss-engineered femtosecond lasers are uniquely designed to perform multiple procedures and give patients a safe and seamless experience. Our GALILEI ColorZ diagnostic devices are now ZEISS VERACITY Surgical compatible and will give you precise measurements to enhance your treatment planning.

For more information, please visit our website at www.ziemerusa.com or contact us directly at [email protected]


Contact Information:
Brad Hurt
Vice President of Business Development & Marketing
[email protected]
866-708-4490


Press Release Service by Newswire.com

Original Source: Ziemer Announces GALILEI ColorZ With ZEISS VERACITY Surgical Compatibility

This news story originally appeared at Health News - on 29 September 2022